Embecta Corp.(EMBC)Earnings, Financials & Key Ratios

EMBC•NASDAQ

$3.11

1.9× P/E·Price updated Jun 25, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryConsumer health and OTC self-care

AboutEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.Show more

Revenue$1.08B-3.8%
EBITDA$380M+75.5%
Net Income$95M+21.8%
EPS (Diluted)1.62+20.9%
Gross Margin62.89%-3.1%
EBITDA Margin35.21%+82.5%
Operating Margin30.48%+96.5%
Net Margin8.83%+26.7%

EMBC Price & Volume

Embecta Corp. (EMBC) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Contraction Challenges Embecta Financial Stability

Investment Thesis • Updated 2026Q2

VerdictNegative

Growth:Contracting

Profitability:Strained

Financial:Vulnerable

Cash Flow:Mixed

Primary Risk:Negative equity and leverage

Key Thesis Takeaways

Embecta faces significant structural headwinds as its core insulin delivery business experiences a 14.4% year-over-year revenue decline, raising concerns regarding the sustainability of its current operating model.
The company's negative equity position of -$626.1M and high debt load of $1.4B create a precarious financial profile that limits strategic flexibility.
Investors should monitor whether the firm can stabilize its volatile gross margins, which dropped from 69.0% in 2024Q3 to 51.4% in 2026Q2, before committing capital to this turnaround effort.

Verdict Logic

the company's inability to maintain positive net income, which fell to -$4.1M in 2026Q2, combined with a deteriorating equity base, suggests significant execution risk that outweighs the current 17.0% dividend yield.

EMBC Growth Metrics

Embecta Corp. (EMBC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-0.09%

3 Years-1.47%

TTM-3.43%

Profit CAGR

10 Years-

5 Years-25.92%

3 Years-24.72%

TTM114.78%

EPS CAGR

10 Years-

5 Years-26.4%

3 Years-25.32%

TTM37.37%

Return on Capital

10 Years54.33%

5 Years43.87%

3 Years28.46%

Last Year37.84%

EMBC Recent Earnings

Embecta Corp. (EMBC) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 5, 2026

Metric

Actual

Est

EPS

$0.27-35.7%

$0.42

Rev

$222M-5.9%

$236M

Q1 2026

Feb 5, 2026

Metric

Actual

Est

EPS

$0.71+6.0%

$0.67

Rev

$261M+1.2%

$258M

Q4 2025

Nov 25, 2025

Metric

Actual

Est

EPS

$0.50-28.6%

$0.70

Rev

$264M+2.2%

$258M

Q3 2025

Aug 8, 2025

Metric

Actual

Est

EPS

$1.12+146.2%

$0.46

Rev

$296M+11.2%

$266M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.27vs $0.42-35.7%	$222Mvs $236M-5.9%
Q1 2026	Feb 5, 2026	$0.71vs $0.67+6.0%	$261Mvs $258M+1.2%
Q4 2025	Nov 25, 2025	$0.50vs $0.70-28.6%	$264Mvs $258M+2.2%
Q3 2025	Aug 8, 2025	$1.12vs $0.46+146.2%	$296Mvs $266M+11.2%

Based on last 12 quarters of dataView full earnings history →

Latest EMBC News

Recent stock market news and headlines for Embecta Corp. (EMBC)

PRNewsWire·14h ago

Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC

LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Peers Comparison

Key metrics vs top competitors for Embecta Corp. (EMBC)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
EMBCEmbecta Corp.Current	$3.11	$184.51M	1.92	-3.8%	8.83%	—	19.1%
UTMDUtah Medical Products, Inc.	$66.87	$212.92M	19.22	-5.83%	28.9%	9.13%	—
LFUSLittelfuse, Inc.	$477.22	$12.07B	-164.56	8.92%	-1.61%	-1.57%	—
NVCRNovoCure Limited	$15.05	$1.71B	-12.34	8.28%	-25.66%	-50.82%	—
ITGRInteger Holdings Corporation	$93.12	$3.2B	32.22	7.57%	7.67%	8.23%	—
MMSIMerit Medical Systems, Inc.	$70.83	$4.22B	33.25	11.66%	9.03%	8.95%	—

Compare EMBC vs Peers

Embecta Corp. (EMBC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs UTMD

Most directly comparable listed peer for EMBC.

Scale Benchmark

vs LLY

Larger-name benchmark to compare EMBC against a more recognizable public peer.

Peer Set

Compare Top 5

vs UTMD, LFUS, NVCR, ITGR

EMBC SEC Filings & Documents

Embecta Corp. (EMBC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Mar 20, 2026·SEC

Material company update

Feb 13, 2026·SEC

10-K Annual Reports

FY 2025

Nov 25, 2025·SEC

FY 2024

Dec 11, 2024·SEC

FY 2023

Nov 29, 2023·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2026

Feb 5, 2026·SEC

FY 2025

Aug 8, 2025·SEC

Get notified when EMBC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

EMBC Frequently Asked Questions

Embecta Corp. (EMBC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Embecta Corp.'s revenue?

Embecta Corp. (EMBC) reported $1.04B in revenue for fiscal year 2025. This represents a 6% decrease from $1.11B in 2019.

How fast is Embecta Corp. growing?

Embecta Corp. (EMBC) saw revenue decline by 3.8% over the past year.

Is EMBC profitable?

Yes, Embecta Corp. (EMBC) is profitable, generating $111.9M in net income for fiscal year 2025 (8.8% net margin).

Dividend & Returns

Does EMBC pay dividends?

Yes, Embecta Corp. (EMBC) pays a dividend with a yield of 19.10%. This makes it attractive for income-focused investors.

What is Embecta Corp.'s free cash flow?

Embecta Corp. (EMBC) generated $174.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in EMBC back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 5, 2026

$0.27vs $0.42-35.7%

$222Mvs $236M-5.9%

Q1 2026

Feb 5, 2026

$0.71vs $0.67+6.0%

$261Mvs $258M+1.2%

Q4 2025

Nov 25, 2025

$0.50vs $0.70-28.6%

$264Mvs $258M+2.2%

Q3 2025

Aug 8, 2025

$1.12vs $0.46+146.2%

$296Mvs $266M+11.2%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

EMBCEmbecta Corp.Current

$3.11

$184.51M

1.92

-3.8%

8.83%

—

19.1%

UTMDUtah Medical Products, Inc.

$66.87

$212.92M

19.22

-5.83%

28.9%

9.13%

—

LFUSLittelfuse, Inc.

$477.22

$12.07B

-164.56

8.92%

-1.61%

-1.57%

—

NVCRNovoCure Limited

$15.05

$1.71B

-12.34

8.28%

-25.66%

-50.82%

—

ITGRInteger Holdings Corporation

$93.12

$3.2B

32.22

7.57%

7.67%

8.23%

—

MMSIMerit Medical Systems, Inc.

$70.83

$4.22B

33.25

11.66%

9.03%

8.95%

—